We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+3.15%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.57B
AUM Growth
+$120M
Cap. Flow
+$109M
Cap. Flow %
6.95%
Top 10 Hldgs %
44.48%
Holding
133
New
28
Increased
33
Reduced
33
Closed
26

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$40.1M
2
CLDX icon
Celldex Therapeutics
CLDX
+$25.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$21.7M
4
HQY icon
HealthEquity
HQY
+$12.8M
5
ARKK icon
ARK Innovation ETF
ARKK
+$9.18M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$60.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$27.8M
3
CTLT
CATALENT, INC.
CTLT
+$24.5M
4
LH icon
Labcorp
LH
+$23.9M
5
MASI
Masimo
MASI
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 72.04%
2 Industrials 1.19%
3 Technology 0.06%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$455B
$114M 7.28%
+286,600
New +$111M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$89.8M 5.74%
833,750
+199,080
+31% +$21.7M
CYH icon
3
Community Health Systems
CYH
$385M
$85M 5.43%
6,389,538
+401,375
+7% +$5.04M
UTHR icon
4
United Therapeutics
UTHR
$26.3B
$84.7M 5.41%
391,920
-52,551
-12% -$10.3M
GSK icon
5
CALL
GSK
GSK
$103B
$66.3M 4.24%
1,202,960
– –
DHR icon
6
Danaher
DHR
$135B
$56M 3.58%
191,820
+24,946
+15% +$6.87M
AZN icon
7
AstraZeneca
AZN
$263B
$55.3M 3.53%
474,612
+29,208
+7% +$3.44M
ASND icon
8
Ascendis Pharma A/S
ASND
$16.7B
$54.3M 3.47%
403,678
-41,525
-9% -$6.18M
AVTR icon
9
Avantor
AVTR
$7.81B
$47.4M 3.03%
1,125,465
-166,549
-13% -$6.56M
BHVN
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$43.4M 2.77%
+315,129
New +$40.1M
ARKG icon
11
ARK Genomic Revolution ETF
ARKG
$1.51B
$40.7M 2.6%
664,484
-25,017
-4% -$1.73M
NVST icon
12
Envista
NVST
$4.28B
$38.3M 2.44%
849,298
+38,417
+5% +$1.58M
AMRN
13
Amarin Corp
AMRN
$284M
$35.6M 2.28%
528,665
-51,585
-9% -$4.27M
MCK icon
14
McKesson
MCK
$98.5B
$33.9M 2.17%
136,111
-25,597
-16% -$5.62M
AZN icon
15
CALL
AstraZeneca
AZN
$263B
$33.3M 2.13%
286,150
+156,000
+120% +$18.4M
AMRX icon
16
Amneal Pharmaceuticals
AMRX
$5.72B
$30.9M 1.97%
6,440,572
-409,262
-6% -$2.04M
IWM icon
17
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$27.8M 1.78%
+125,000
New +$28.2M
IWO icon
18
PUT
iShares Russell 2000 Growth ETF
IWO
$14.5B
$26.4M 1.68%
+90,000
New +$27.1M
GSK icon
19
GSK
GSK
$103B
$25M 1.6%
453,764
+132,441
+41% +$6.89M
CLDX icon
20
Celldex Therapeutics
CLDX
$2.77B
$22.9M 1.46%
+592,478
New +$25.8M
VRTX icon
21
CALL
Vertex Pharmaceuticals
VRTX
$121B
$20.7M 1.32%
94,100
-79,200
-46% -$15.4M
OCDX
22
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
$19M 1.21%
886,140
-28,846
-3% -$568K
RCM
23
DELISTED
R1 RCM Inc. Common Stock
RCM
$18.7M 1.19%
733,132
-31,648
-4% -$759K
CNC icon
24
Centene
CNC
$31.3B
$18.5M 1.18%
224,613
+83,506
+59% +$6.12M
TEVA icon
25
Teva Pharmaceuticals
TEVA
$35.9B
$18.4M 1.18%
2,301,498
-1,253,306
-35% -$11.3M
1
2 3 4 5

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q4 2021 Portfolio in Review

As of Q4 2021, Eversept Partners held 133 positions worth $1.57B, up 8.3% from $1.45B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Eversept Partners deployed $109M of net new capital in Q4 2021, opening 28 new positions and adding to 33 existing holdings. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 315,129 shares worth $43.4M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 80% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Labcorp, an estimated $23.9M trimmed.

  • Eversept Partners's largest Q4 2021 buy was Biohaven Pharmaceutical Holding Company Ltd.: 315,129 shares worth $43.4M.
  • Eversept Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021, an estimated $21.7M increase.
  • Eversept Partners's biggest Q4 2021 reduction was Labcorp, cutting an estimated $23.9M.
  • Eversept Partners fully exited Acceleron Pharma in Q4 2021, selling an estimated $60.1M.
  • Eversept Partners's ten largest holdings make up 44% of its $1.57B portfolio in Q4 2021.
  • Eversept Partners opened 28 new positions and closed 26 in Q4 2021.
  • Eversept Partners's portfolio value rose 8.3% quarter-over-quarter to $1.57B.

Based on Eversept Partners's 13F filing for Q4 2021, filed 14 Feb 2022.